AEs and clinical laboratory tests were evaluated throughout treatment per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v5.0. Tumor response was evaluated by radiological imaging per RECIST 1.1 and irRECIST, at baseline and every 6 weeks until progression,...
Victoria Casado20, Manuel Constenla21, María Gutiérrez22, Alba Dosil23 and Antonio González-Martín5,24 Abstract Background: Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC)...
It is noted that a rich source of data on ovarian cancer can be found in medical records from primary care across the country. The need to standardise terminology and improve Read coding in primary care is suggested to improve quality of such data. The author also recommends measuring CA125...
Ovarian cancer is a complicated disease. There are multiple histological subtypes, with different clinical behaviors, different prognoses, and molecular signatures [2]. New data have demonstrated that it is High Grade Serous Carcinoma (HGSC) of the ovary (and of the peritoneum and the fallopian tub...
Ovarian cancer is the deadliest gynaecologic malignancy. Despite progresses in chemotherapy and ultra-radical surgeries, this locally metastatic disease presents a high rate of local recurrence advocating for the role of a peritoneal niche. For several years, it was believed that tumor initiation, prog...
Chemoresistance and metastasis are the major challenges for the current ovarian cancer treatment. Understanding the mechanisms of ovarian cancer progression and metastasis is critically important for developing novel therapies. The advances in extracellu
Cancer is the leading cause of death worldwide. Fortunately, the survival rate of cancer continues to rise, owing to advances in cancer treatments. However, these treatments are gonadotoxic and cause infertility. Ovarian tissue cryopreservation and transplantation (OTCT) is the most flexible option...
“In the NOVA trial, maintenance is in the title, but half the patients still have cancer. How can I call that maintenance if they had partial responses until their last treatment?” The experts agreed the terminology was imperfect, and Herzog suggested the NOVA trial was more like a switch...
The Drug Development Unit is supported by Cancer Research UK through a programme grant to the Section of Medicine, Institute of Cancer Research, and through an Experimental Cancer Medical Centre (ECMC) grant (C51/A7401). It is also supported by the Department of Health through the ECMC grant ...
During an international workshop held in September 1998, a group of specialists in the field of ovarian cancer reached consensus on a number of issues with implications for standard practice and for research of advanced epithelial ovarian cancer. Methods Five groups of experts considered several issue...